A Zamora1, F Fernández de Bobadilla, C Carrion, G Vázquez, G Paluzie, R Elosua, M Vilaseca, A Martín-Urda, A Rivera, N Plana, L Masana. 1. TransLab Research Group, Medical Sciences Department, University of Girona, Catalonia, Spain; Lipid and Atherosclerosis Unit, Hospital de Blanes, Girona, Spain; Heracles Cardiovascular Network, Spain; Department of Internal Medicine, Hospital de Blanes, Girona, Spain. Electronic address: azamorac.zamora@gmail.com.
Abstract
UNLABELLED: Pilot study to validate a Computerized Decision Support Systems (CDS) (HTE-DLP) for improving treatment of hyperlipidemia. METHODS:HTE-DLP was programmed to offer automatic specific reminders for lipid treatment. Seventy-seven patients with high cardiovascular risk were randomized. 10 expert physicians in cardiovascular-risk management were recruited. We assessed number of patients at LDL <70 mg/dl after 12 weeks of treatment. RESULTS: A greater proportion of intervention group reached the LDL-C <70 mg/ml [55.0% vs 12.5%, p = 0.003; OR: 3.26 IC (1.16-9.15)]. "High potency statins" and combined therapy were used more frequently in the intervention group than the control group (p = 0.001). Seven adverse effects were documented in the intervention group and two in the control group. An acceptable relationship was observed with regard to costeffectiveness in the intervention group. Physicians expressed good agreement with HTE-DLP (86.1%) and comfortable ease-of-use (85%). CONCLUSIONS: Use of a CDSS in high-risk cardiovascular patients resulted in a significant reduction in LDL-C levels.
RCT Entities:
UNLABELLED: Pilot study to validate a Computerized Decision Support Systems (CDS) (HTE-DLP) for improving treatment of hyperlipidemia. METHODS: HTE-DLP was programmed to offer automatic specific reminders for lipid treatment. Seventy-seven patients with high cardiovascular risk were randomized. 10 expert physicians in cardiovascular-risk management were recruited. We assessed number of patients at LDL <70 mg/dl after 12 weeks of treatment. RESULTS: A greater proportion of intervention group reached the LDL-C <70 mg/ml [55.0% vs 12.5%, p = 0.003; OR: 3.26 IC (1.16-9.15)]. "High potency statins" and combined therapy were used more frequently in the intervention group than the control group (p = 0.001). Seven adverse effects were documented in the intervention group and two in the control group. An acceptable relationship was observed with regard to costeffectiveness in the intervention group. Physicians expressed good agreement with HTE-DLP (86.1%) and comfortable ease-of-use (85%). CONCLUSIONS: Use of a CDSS in high-risk cardiovascular patients resulted in a significant reduction in LDL-C levels.
Authors: Kunal N Karmali; Stephen D Persell; Pablo Perel; Donald M Lloyd-Jones; Mark A Berendsen; Mark D Huffman Journal: Cochrane Database Syst Rev Date: 2017-03-14
Authors: Verughese Jacob; Anilkrishna B Thota; Sajal K Chattopadhyay; Gibril J Njie; Krista K Proia; David P Hopkins; Murray N Ross; Nicolaas P Pronk; John M Clymer Journal: J Am Med Inform Assoc Date: 2017-05-01 Impact factor: 4.497
Authors: Randi E Foraker; Bobbie Kite; Marjorie M Kelley; Albert M Lai; Caryn Roth; Marcelo A Lopetegui; Abigail B Shoben; Michael Langan; Nicole L Rutledge; Philip R O Payne Journal: EGEMS (Wash DC) Date: 2015-06-18
Authors: Randi E Foraker; Abigail B Shoben; Marjorie M Kelley; Albert M Lai; Marcelo A Lopetegui; Rebecca D Jackson; Michael A Langan; Philip R O Payne Journal: Prev Med Rep Date: 2016-07-13
Authors: Laney K Jones; Stephanie Tilberry; Christina Gregor; Lauren H Yaeger; Yirui Hu; Amy C Sturm; Terry L Seaton; Thomas J Waltz; Alanna K Rahm; Anne Goldberg; Ross C Brownson; Samuel S Gidding; Marc S Williams; Michael R Gionfriddo Journal: Implement Sci Date: 2021-04-13 Impact factor: 7.327
Authors: Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio Journal: Adv Ther Date: 2015-10-26 Impact factor: 3.845